Morgan Stanley analyst Terence Flynn raised the firm’s price target on Biogen (BIIB) to $156 from $149 and keeps an Equal Weight rating on the shares. The firm expects many of the policy overhangs that dominated the biopharma conversation this year to wane in 2026, bringing the focus back to fundamentals, the analyst tells investors in a 2026 outlook note for the group.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Midday Fly By: SK Hynix weighs U.S. listing, GE Vernova doubles dividend
- Amazon initiated, GE Vernova upgraded: Wall Street’s top analyst calls
- Video: GE Vernova jumps after buyback boosted, dividend doubled
- Biogen downgraded to Reduce from Hold at HSBC
- Biogen’s Strategic Growth and Innovative Edge Justify Buy Rating